Aduro Completes $137 Million Initial Public Offering

Palo Alto– April 30, 2015 – Cooley advised Aduro Biotech, Inc. on its $137 million initial public offering. Aduro is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company trades on The NASDAQ Global Market under the symbol "ADRO." Aduro also raised an additional $25 million in a private placement with Novartis Institutes for BioMedical Research, Inc., which closed concurrently with the offering.

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Barbara Kosacz  Senior Counsel Palo Alto
Michael Tenta  Partner Palo Alto
Natasha Leskovsek  Of Counsel Washington, DC
Lesse Castleberry  Senior Counsel New York
Jennifer Raab  Special Counsel Palo Alto
Bill Christiansen  Partner Seattle
Phil Mitchell  Partner New York